Navigation Links
Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
Date:2/13/2008

SOUTH SAN FRANCISCO, Calif., Feb. 13 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that it completed enrollment of patients in the maximum tolerated dose (MTD) cohort expansion segment of its Phase 1/2a trial of RAV12, an anti-cancer monoclonal antibody. The trial enrolled patients with cancers that express the RAAG12 antigen, particularly those of gastrointestinal origin. All patients in the trial have undergone radiographic re-evaluation to assess their response to treatment. Based on this assessment, two patients remain on study drug beyond the original treatment period. A total of four patients received extended therapy in both the original cohort and the expanded cohort of this trial.

"We continue to be pleased with our advances with RAV12 and the indications of its potential therapeutic value." said George Schreiner, M.D., Ph.D., chief executive officer of Raven biotechnologies.

RAAG12 is a glycotope (sugar structure) that is widely found on the surface of tumor cells of many kinds of cancer, particularly cancers of the gastrointestinal tract (adenocarcinomas of gastroesophageal, pancreatic and colorectal origin). RAV12, Raven's lead clinical monoclonal antibody drug candidate, targets the RAAG12 antigen.

An analysis of data from this trial is expected in the second or third quarter of this year. The analysis will produce an evaluation of safety, definitive pharmacokinetics, evaluation of immunogenicity, and estimates of efficacy in a refractory patient population.

The appropriate dose and schedule of RAV12 previously was chosen in a dose-escalation segment of the Phase 1/2a trial that involved 33 patients. This trial revealed that a fractionated dosing regimen provided an improved side effect profile for the antibody. The recently concluded MTD Cohort Expansion segment involved 20 additional patients.

The trial was conducted at five institutions in the United States: The Sarah Cannon Cancer Center in Nashville, TN; The Fox Chase Cancer Center in Philadelphia, PA; Premiere Oncology in Santa Monica, CA; Georgetown University Medical Center in Washington, DC; and The University of Miami Medical Center in Miami, FL.

The RAV12 Phase 2 Program is expected to begin in the first quarter of 2008 when a first patient is enrolled in a study of gemcitabine plus RAV12 for the treatment of patients with metastatic pancreatic cancer. An additional Phase 2 study employing RAV12 is planned to begin in the second half of this year.

About RAV12

RAV12 is a novel, chimeric monoclonal antibody that is directed against a primate-specific glycotope (sugar structure) that is widely displayed on the surfaces of tumor cells, particularly those of gastrointestinal origin (gastroesophageal, pancreatic, and colorectal cancers). Preclinical studies have demonstrated that RAV12 may kill tumor cells in a number of ways: first, the antibody is directly cytotoxic to a human colon cancer cell line in vitro through induction of oncotic cell death, a form of cell death characterized by cell and organelle swelling and loss of membrane integrity; second, the antibody mediates antibody-dependent cellular cytotoxicity; third, the antibody mediates complement dependent cell killing; and finally, the antibody alters cellular signaling required for cell survival. RAV12 is highly efficacious in human colon, gastric, and pancreatic tumor xenograft models in vivo and has been found to be well tolerated in repeat dose primate toxicology studies.

About GI Cancers

Adenocarcinomas are malignant tumors of the epithelial cells that line glands or viscera. They typically spread by way of the circulatory or lymphatic systems and are poorly treated after metastatic spread. More than 90 percent of colon, stomach and pancreatic tumor specimens express the RAV12 defined antigen, RAAG12. Adenocarcinomas arising elsewhere, such as breast, endometrial, ovarian, lung and prostate, display the antigen at lower frequency.

About Raven

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for optimizing the production of MAbs targeting cell-surface proteins, including the use of human tissue-specific progenitor and tumor stem cell lines developed at Raven.

To date Raven has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast, and ovarian cancer.


'/>"/>
SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
3. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)...  Astute Medical, Inc., developer of biomarkers for better ... at the 2017 National Kidney Foundation (NKF) Spring ... April 22. Physicians will present data on two biomarkers, ... for acute kidney injury (AKI) during the management of ... Elevated levels of TIMP-2 and IGFBP-7 have been ...
(Date:4/18/2017)... , April 18, 2017 Research and ... the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast ... ... molecular imaging equipment revenues as well as growth in the ... will provide value to market participants that design and manufacture ...
(Date:4/18/2017)... TAMPA, Fla. , April 18, 2017 WellCare ... Health Plans, Inc. (NYSE: WCG), announced today it will award ... Kentucky to reduce tobacco use and promote smoke-free ... Center for Smoke-Free Policy conference hosted by the University of ... first time WellCare, the state,s largest Medicaid managed care organization, ...
Breaking Medicine Technology:
(Date:4/21/2017)... , ... April 21, 2017 , ... ... system, has partnered with O2X , an active lifestyle company that provides ... improving the health of firefighters, police offers, first responders, military officers and others ...
(Date:4/21/2017)... Santa Rosa, CA (PRWEB) , ... April 21, ... ... with St. Joseph Health held the much anticipated Regional Primary Care Spring Symposium ... vital role in the local medical community, offering physicians and healthcare providers an ...
(Date:4/21/2017)... City, UT (PRWEB) , ... April 21, 2017 , ... ... solutions, recently partnered with Advanced Patient Care of Utah (APCUT) and has appointed Rex ... for the next chapter of growth for our agency and our ability to provide ...
(Date:4/21/2017)... ... April 21, 2017 , ... During April 21-23, Super-Sod will join the ... festival offers entertainment for everyone — from the avid gardener to the landscape admirer ... high quality event held in a grand venue, and we are certainly looking forward ...
(Date:4/21/2017)... ... April 21, 2017 , ... National pest management association survey conducted in ... bed bug infestations over the 5-year period. In 2015 10% or US$750 million per ... bed bug infested properties. , The health and economic consequences of bed bug ...
Breaking Medicine News(10 mins):